| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 59 | 2023 | 138 | 5.390 |
Why?
|
| Carcinoma, Squamous Cell | 36 | 2022 | 164 | 3.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 41 | 2021 | 240 | 2.420 |
Why?
|
| Laryngeal Neoplasms | 8 | 2023 | 28 | 1.620 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2022 | 203 | 1.340 |
Why?
|
| Chemoradiotherapy | 12 | 2023 | 57 | 1.310 |
Why?
|
| Antineoplastic Agents | 10 | 2016 | 198 | 1.070 |
Why?
|
| Tongue Neoplasms | 6 | 2021 | 18 | 1.000 |
Why?
|
| Mouth Neoplasms | 5 | 2018 | 20 | 0.990 |
Why?
|
| Neck Dissection | 9 | 2020 | 18 | 0.900 |
Why?
|
| Aged | 72 | 2023 | 7572 | 0.860 |
Why?
|
| Combined Modality Therapy | 35 | 2021 | 294 | 0.830 |
Why?
|
| Middle Aged | 70 | 2021 | 8134 | 0.820 |
Why?
|
| Retrospective Studies | 31 | 2023 | 3122 | 0.810 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 215 | 0.800 |
Why?
|
| Drug Utilization | 2 | 2020 | 20 | 0.790 |
Why?
|
| Humans | 103 | 2023 | 23541 | 0.790 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 358 | 0.780 |
Why?
|
| Neoplasm Invasiveness | 6 | 2021 | 90 | 0.780 |
Why?
|
| Female | 77 | 2021 | 13239 | 0.740 |
Why?
|
| Male | 77 | 2021 | 12743 | 0.740 |
Why?
|
| Adult | 60 | 2020 | 7168 | 0.680 |
Why?
|
| Disease-Free Survival | 24 | 2019 | 172 | 0.650 |
Why?
|
| Nuclear Physics | 6 | 2014 | 12 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 5 | 2012 | 62 | 0.620 |
Why?
|
| Head | 1 | 2019 | 18 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2011 | 605 | 0.620 |
Why?
|
| Neck | 1 | 2019 | 23 | 0.620 |
Why?
|
| Oropharyngeal Neoplasms | 5 | 2022 | 19 | 0.620 |
Why?
|
| Models, Theoretical | 6 | 2014 | 77 | 0.610 |
Why?
|
| Morphine | 1 | 2019 | 70 | 0.600 |
Why?
|
| Length of Stay | 2 | 2023 | 305 | 0.590 |
Why?
|
| Radiotherapy Dosage | 18 | 2016 | 94 | 0.570 |
Why?
|
| Treatment Outcome | 32 | 2020 | 3093 | 0.550 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 1492 | 0.550 |
Why?
|
| Pain, Postoperative | 4 | 2021 | 282 | 0.530 |
Why?
|
| Fluorouracil | 29 | 2012 | 46 | 0.530 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 3 | 2021 | 29 | 0.520 |
Why?
|
| Survival Analysis | 16 | 2021 | 245 | 0.460 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 79 | 0.450 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 83 | 0.450 |
Why?
|
| Prognosis | 18 | 2019 | 749 | 0.430 |
Why?
|
| Elementary Particles | 4 | 2014 | 8 | 0.420 |
Why?
|
| Hydroxyurea | 26 | 2012 | 29 | 0.420 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 19 | 0.410 |
Why?
|
| Neoplasms, Second Primary | 6 | 2016 | 36 | 0.400 |
Why?
|
| Adenocarcinoma | 3 | 2021 | 135 | 0.400 |
Why?
|
| Quinazolines | 5 | 2012 | 17 | 0.400 |
Why?
|
| Induction Chemotherapy | 6 | 2016 | 13 | 0.390 |
Why?
|
| Lymph Nodes | 4 | 2009 | 72 | 0.380 |
Why?
|
| Aged, 80 and over | 26 | 2020 | 3767 | 0.360 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2011 | 1 | 0.350 |
Why?
|
| Tracheotomy | 1 | 2011 | 3 | 0.350 |
Why?
|
| Drug Prescriptions | 2 | 2021 | 19 | 0.350 |
Why?
|
| Airway Obstruction | 1 | 2011 | 18 | 0.350 |
Why?
|
| Hyperhidrosis | 1 | 2010 | 1 | 0.350 |
Why?
|
| Sympathectomy | 1 | 2010 | 3 | 0.350 |
Why?
|
| Spasm | 1 | 2010 | 2 | 0.350 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.350 |
Why?
|
| Ischemia | 1 | 2010 | 23 | 0.340 |
Why?
|
| Survival Rate | 14 | 2021 | 323 | 0.340 |
Why?
|
| Vascular Diseases | 1 | 2010 | 35 | 0.340 |
Why?
|
| Upper Extremity | 1 | 2010 | 51 | 0.330 |
Why?
|
| Cohort Studies | 8 | 2020 | 1465 | 0.330 |
Why?
|
| Deglutition Disorders | 3 | 2011 | 31 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2012 | 82 | 0.320 |
Why?
|
| Paclitaxel | 16 | 2012 | 49 | 0.320 |
Why?
|
| Narcotics | 2 | 2020 | 34 | 0.320 |
Why?
|
| Analgesia | 2 | 2020 | 35 | 0.310 |
Why?
|
| Betacoronavirus | 2 | 2020 | 69 | 0.310 |
Why?
|
| Preoperative Care | 3 | 2020 | 112 | 0.290 |
Why?
|
| Pneumonia, Aspiration | 1 | 2007 | 7 | 0.280 |
Why?
|
| Robotic Surgical Procedures | 2 | 2020 | 26 | 0.280 |
Why?
|
| Disease Management | 2 | 2020 | 100 | 0.270 |
Why?
|
| ErbB Receptors | 4 | 2012 | 54 | 0.260 |
Why?
|
| Risk Assessment | 7 | 2019 | 555 | 0.260 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2015 | 50 | 0.260 |
Why?
|
| Parotid Neoplasms | 2 | 2020 | 14 | 0.260 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 87 | 0.240 |
Why?
|
| Facial Neoplasms | 2 | 1996 | 2 | 0.240 |
Why?
|
| Esophageal Neoplasms | 2 | 2022 | 50 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2012 | 31 | 0.220 |
Why?
|
| Papillomaviridae | 4 | 2022 | 17 | 0.220 |
Why?
|
| Otolaryngology | 2 | 2020 | 24 | 0.210 |
Why?
|
| Elementary Particle Interactions | 2 | 2013 | 5 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2019 | 168 | 0.200 |
Why?
|
| Carcinoma | 2 | 2012 | 68 | 0.200 |
Why?
|
| Quality of Life | 10 | 2012 | 565 | 0.200 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 53 | 0.200 |
Why?
|
| Surgical Flaps | 3 | 2008 | 50 | 0.200 |
Why?
|
| Mouth | 2 | 2011 | 12 | 0.200 |
Why?
|
| Facial Nerve | 2 | 2020 | 10 | 0.190 |
Why?
|
| Dissection | 2 | 2020 | 23 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 4 | 2012 | 14 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 6 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.190 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2022 | 3 | 0.190 |
Why?
|
| Biomarkers | 2 | 2014 | 482 | 0.180 |
Why?
|
| Human papillomavirus 16 | 2 | 2019 | 6 | 0.180 |
Why?
|
| Radiography | 4 | 2014 | 555 | 0.180 |
Why?
|
| Immunotherapy | 1 | 2021 | 50 | 0.180 |
Why?
|
| Deglutition | 3 | 2010 | 10 | 0.180 |
Why?
|
| Radiotherapy | 7 | 2011 | 32 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 41 | 0.180 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.170 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2011 | 6 | 0.170 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 9 | 0.170 |
Why?
|
| Cetuximab | 2 | 2021 | 5 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2021 | 24 | 0.170 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2020 | 5 | 0.170 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2020 | 4 | 0.170 |
Why?
|
| Glottis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Parotid Gland | 1 | 2020 | 17 | 0.170 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 24 | 0.170 |
Why?
|
| Prescriptions | 1 | 2020 | 16 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 12 | 0.170 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 1 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2022 | 185 | 0.170 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 68 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 27 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 57 | 0.160 |
Why?
|
| Pain Management | 1 | 2021 | 132 | 0.160 |
Why?
|
| Free Tissue Flaps | 1 | 2019 | 14 | 0.160 |
Why?
|
| Patient Compliance | 1 | 2020 | 145 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2020 | 255 | 0.160 |
Why?
|
| Prostheses and Implants | 2 | 1997 | 129 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 169 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 63 | 0.150 |
Why?
|
| Radiometry | 2 | 2004 | 25 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 85 | 0.150 |
Why?
|
| Sarcoma | 1 | 2021 | 142 | 0.140 |
Why?
|
| Thoracic Duct | 1 | 2017 | 3 | 0.140 |
Why?
|
| Lymphatic Diseases | 1 | 2017 | 4 | 0.140 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 105 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2021 | 1532 | 0.140 |
Why?
|
| Deoxycytidine | 3 | 2011 | 20 | 0.130 |
Why?
|
| Postoperative Complications | 3 | 2020 | 837 | 0.130 |
Why?
|
| Adolescent | 8 | 2020 | 1952 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 1997 | 71 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 54 | 0.130 |
Why?
|
| Mesons | 2 | 2014 | 4 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 1745 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2013 | 20 | 0.130 |
Why?
|
| Facial Bones | 1 | 1996 | 1 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 32 | 0.130 |
Why?
|
| Hemangiopericytoma | 1 | 1996 | 2 | 0.120 |
Why?
|
| Probability | 5 | 2008 | 73 | 0.120 |
Why?
|
| Mouth Mucosa | 1 | 1996 | 10 | 0.120 |
Why?
|
| Contrast Media | 2 | 2009 | 60 | 0.120 |
Why?
|
| Algorithms | 2 | 2021 | 317 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 2 | 0.110 |
Why?
|
| Chorionic Gonadotropin | 1 | 2014 | 16 | 0.110 |
Why?
|
| Databases, Factual | 3 | 2021 | 316 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cicatrix | 1 | 1994 | 8 | 0.110 |
Why?
|
| DNA Repair | 1 | 2014 | 7 | 0.110 |
Why?
|
| Pandemics | 3 | 2020 | 207 | 0.110 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 16 | 0.110 |
Why?
|
| Burns | 1 | 1994 | 16 | 0.110 |
Why?
|
| Neutrons | 1 | 2014 | 2 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 47 | 0.110 |
Why?
|
| Esophagoscopy | 2 | 2010 | 15 | 0.110 |
Why?
|
| Organ Preservation | 2 | 2011 | 6 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 44 | 0.110 |
Why?
|
| Genomics | 1 | 2014 | 51 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 167 | 0.110 |
Why?
|
| Burns, Chemical | 1 | 1993 | 1 | 0.110 |
Why?
|
| Caustics | 1 | 1993 | 1 | 0.110 |
Why?
|
| Cosmetics | 1 | 1993 | 1 | 0.110 |
Why?
|
| Facial Injuries | 1 | 1993 | 1 | 0.110 |
Why?
|
| Remission Induction | 6 | 2016 | 89 | 0.110 |
Why?
|
| Pharynx | 1 | 1993 | 11 | 0.110 |
Why?
|
| Laryngostenosis | 1 | 1993 | 2 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 26 | 0.100 |
Why?
|
| Tracheal Stenosis | 1 | 1993 | 6 | 0.100 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2012 | 2 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 4 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 231 | 0.100 |
Why?
|
| Cartilage | 1 | 1993 | 70 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2009 | 9 | 0.100 |
Why?
|
| DNA | 1 | 2012 | 95 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 322 | 0.100 |
Why?
|
| Risk Factors | 4 | 2014 | 1997 | 0.100 |
Why?
|
| Laryngectomy | 2 | 2023 | 16 | 0.100 |
Why?
|
| Speech | 2 | 2010 | 21 | 0.100 |
Why?
|
| Salvage Therapy | 2 | 2023 | 32 | 0.090 |
Why?
|
| Protons | 1 | 2013 | 84 | 0.090 |
Why?
|
| Time Factors | 6 | 2012 | 1293 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 276 | 0.090 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 12 | 0.090 |
Why?
|
| Carboplatin | 6 | 2012 | 24 | 0.090 |
Why?
|
| Biopsy | 2 | 2009 | 193 | 0.090 |
Why?
|
| United States | 4 | 2021 | 1837 | 0.090 |
Why?
|
| Lymphangioma | 1 | 1991 | 2 | 0.090 |
Why?
|
| Skin | 1 | 2012 | 119 | 0.090 |
Why?
|
| Supraglottitis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Illinois | 3 | 2007 | 222 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 297 | 0.090 |
Why?
|
| Iloprost | 1 | 2010 | 1 | 0.090 |
Why?
|
| Infusions, Parenteral | 1 | 2010 | 10 | 0.090 |
Why?
|
| Margins of Excision | 2 | 2021 | 29 | 0.090 |
Why?
|
| Incidence | 3 | 2008 | 644 | 0.090 |
Why?
|
| Tongue | 2 | 2021 | 8 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2010 | 45 | 0.090 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 28 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2000 | 6 | 0.090 |
Why?
|
| Esophageal Stenosis | 1 | 2010 | 3 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 443 | 0.080 |
Why?
|
| Dilatation | 1 | 2010 | 10 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2022 | 379 | 0.080 |
Why?
|
| Osteoradionecrosis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 276 | 0.080 |
Why?
|
| Bevacizumab | 4 | 2011 | 22 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2008 | 76 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 244 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2011 | 84 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2009 | 114 | 0.080 |
Why?
|
| Mass Screening | 2 | 2020 | 168 | 0.080 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2008 | 2 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 67 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2020 | 429 | 0.070 |
Why?
|
| Taxoids | 1 | 2007 | 11 | 0.070 |
Why?
|
| Wound Healing | 2 | 2000 | 119 | 0.060 |
Why?
|
| Recombinant Proteins | 5 | 2010 | 168 | 0.060 |
Why?
|
| Neoplasm Metastasis | 4 | 2012 | 102 | 0.060 |
Why?
|
| Disease Progression | 5 | 2011 | 530 | 0.060 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2006 | 4 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2005 | 18 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2000 | 209 | 0.060 |
Why?
|
| Registries | 1 | 2006 | 179 | 0.060 |
Why?
|
| Smoking | 3 | 2014 | 168 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2006 | 505 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2003 | 35 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 340 | 0.050 |
Why?
|
| Carotid Body Tumor | 1 | 2004 | 1 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2012 | 9 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 112 | 0.050 |
Why?
|
| Cancer Care Facilities | 1 | 2003 | 6 | 0.050 |
Why?
|
| Travel | 1 | 2003 | 14 | 0.050 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2003 | 4 | 0.050 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 154 | 0.050 |
Why?
|
| Maxillary Neoplasms | 1 | 2003 | 1 | 0.050 |
Why?
|
| Maxillary Sinus | 1 | 2003 | 1 | 0.050 |
Why?
|
| Carcinoma, Verrucous | 1 | 2003 | 1 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2003 | 44 | 0.050 |
Why?
|
| Cisplatin | 4 | 2010 | 60 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 1045 | 0.050 |
Why?
|
| Patient Selection | 1 | 2003 | 170 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Retreatment | 2 | 2012 | 8 | 0.050 |
Why?
|
| Intubation, Intratracheal | 2 | 1993 | 87 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 23 | 0.050 |
Why?
|
| Infant | 2 | 1993 | 488 | 0.050 |
Why?
|
| Phototherapy | 1 | 2021 | 27 | 0.040 |
Why?
|
| Chicago | 2 | 2020 | 818 | 0.040 |
Why?
|
| Trachea | 1 | 2022 | 39 | 0.040 |
Why?
|
| Apoptosis | 1 | 2022 | 198 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.040 |
Why?
|
| United Kingdom | 1 | 2020 | 41 | 0.040 |
Why?
|
| Interferon-alpha | 3 | 2010 | 30 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 19 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 2000 | 1 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 29 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 271 | 0.040 |
Why?
|
| Video Recording | 1 | 2000 | 30 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2000 | 35 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2021 | 128 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 37 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 40 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.040 |
Why?
|
| Uracil | 1 | 1999 | 4 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 1999 | 9 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 44 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 168 | 0.040 |
Why?
|
| Attitude to Health | 1 | 1999 | 94 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Camptothecin | 2 | 2010 | 3 | 0.040 |
Why?
|
| Child | 2 | 2012 | 1178 | 0.040 |
Why?
|
| Voice | 2 | 1999 | 5 | 0.040 |
Why?
|
| Lymphography | 1 | 2017 | 2 | 0.030 |
Why?
|
| Polyesters | 1 | 1997 | 2 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2018 | 61 | 0.030 |
Why?
|
| Durapatite | 1 | 1997 | 8 | 0.030 |
Why?
|
| Stainless Steel | 1 | 1997 | 14 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 1997 | 33 | 0.030 |
Why?
|
| Alloys | 1 | 1997 | 76 | 0.030 |
Why?
|
| Vocal Cord Paralysis | 1 | 1997 | 2 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 1997 | 5 | 0.030 |
Why?
|
| Granuloma, Foreign-Body | 1 | 1997 | 3 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2012 | 18 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 1997 | 11 | 0.030 |
Why?
|
| Leucovorin | 2 | 2010 | 8 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2003 | 99 | 0.030 |
Why?
|
| Titanium | 1 | 1997 | 141 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 271 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 1997 | 43 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 648 | 0.030 |
Why?
|
| Everolimus | 1 | 2016 | 3 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2011 | 70 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 18 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2008 | 229 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 112 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2006 | 234 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2014 | 1 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 5 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 9 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 9 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 54 | 0.030 |
Why?
|
| Electrons | 1 | 2014 | 16 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2014 | 24 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 453 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2009 | 220 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2014 | 42 | 0.030 |
Why?
|
| Drug Packaging | 1 | 1993 | 1 | 0.030 |
Why?
|
| Child Welfare | 1 | 1993 | 16 | 0.030 |
Why?
|
| Pregnancy | 1 | 2014 | 322 | 0.030 |
Why?
|
| Pulmonary Atelectasis | 1 | 1993 | 4 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 324 | 0.030 |
Why?
|
| Tracheostomy | 1 | 1993 | 21 | 0.030 |
Why?
|
| Laser Coagulation | 1 | 1993 | 3 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 1993 | 8 | 0.030 |
Why?
|
| Traction | 1 | 1993 | 28 | 0.020 |
Why?
|
| Platinum | 1 | 2012 | 4 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 330 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1993 | 117 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 48 | 0.020 |
Why?
|
| Pneumonia | 1 | 1993 | 69 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 36 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2014 | 401 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 163 | 0.020 |
Why?
|
| Lung | 1 | 1993 | 153 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 83 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 7 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 15 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1993 | 583 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2011 | 4 | 0.020 |
Why?
|
| Guanine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Glutamates | 1 | 2011 | 7 | 0.020 |
Why?
|
| Gastrostomy | 1 | 2010 | 9 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 52 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 132 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 269 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 7 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 9 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 11 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 59 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 16 | 0.020 |
Why?
|
| Thoracic Arteries | 1 | 2008 | 2 | 0.020 |
Why?
|
| Microcirculation | 1 | 2008 | 25 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 27 | 0.020 |
Why?
|
| Microsurgery | 1 | 2008 | 39 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1991 | 908 | 0.020 |
Why?
|
| Fascia | 1 | 2006 | 6 | 0.020 |
Why?
|
| Forearm | 1 | 2006 | 18 | 0.020 |
Why?
|
| Thigh | 1 | 2006 | 28 | 0.020 |
Why?
|
| Graft Survival | 1 | 2006 | 84 | 0.020 |
Why?
|
| Reoperation | 1 | 2008 | 767 | 0.010 |
Why?
|
| Angiography | 1 | 2004 | 25 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 102 | 0.010 |
Why?
|
| Cause of Death | 1 | 2004 | 58 | 0.010 |
Why?
|
| Hospitals, University | 1 | 2003 | 23 | 0.010 |
Why?
|
| Bias | 1 | 2003 | 24 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 196 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2003 | 11 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 83 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 431 | 0.010 |
Why?
|
| Tretinoin | 1 | 2000 | 15 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 30 | 0.010 |
Why?
|
| Choice Behavior | 1 | 1999 | 41 | 0.010 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 1999 | 1 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 115 | 0.010 |
Why?
|
| Health Status | 1 | 1999 | 203 | 0.010 |
Why?
|
| Diet | 1 | 1999 | 182 | 0.010 |
Why?
|
| Decision Making | 1 | 1999 | 187 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 603 | 0.010 |
Why?
|
| Animals | 2 | 1995 | 3293 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 1999 | 778 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1999 | 429 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 128 | 0.010 |
Why?
|
| Aluminum Silicates | 1 | 1993 | 1 | 0.010 |
Why?
|
| Neodymium | 1 | 1993 | 1 | 0.010 |
Why?
|
| Yttrium | 1 | 1993 | 1 | 0.010 |
Why?
|
| Smoke Inhalation Injury | 1 | 1993 | 2 | 0.010 |
Why?
|
| Pulmonary Emphysema | 1 | 1993 | 2 | 0.010 |
Why?
|
| Blood Vessels | 1 | 1993 | 14 | 0.010 |
Why?
|
| Smoke | 1 | 1993 | 4 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1993 | 23 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1993 | 22 | 0.010 |
Why?
|
| Respiratory Muscles | 1 | 1993 | 15 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1993 | 18 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 312 | 0.010 |
Why?
|
| Rats | 1 | 1993 | 621 | 0.010 |
Why?
|